i dont know -making educated guesses by assimilati

i dont know -making educated guesses by assimilating all the info we've been given- ca july 2017 they made the decision to seek patent licensing sales in europe bc internal revenues were not sufficient for the growth they wanted- july 2017 pr

9-12 months in they had to pay maintenance fees on those eu patents of 30k which came from a private investor - not profit- april 2018 pr?
same with their contribution to the pretest study

lack of net revenue or sufficient net revenue is the reason imo they dont upgrade their otc classification-which would have a positive cost benefit and aid their negotiations

of course, at any point in any month,the combination of their cutting cost (e.g BB personally putting orders together for shipment as reported by eudius a long time ago) and incrementally increasing sales could turn the corner to net revenue or sufficient net revenue to grow internally-a stage they have not reached yet-from the evidence and their updates

"maybe the n assay isn't valuable without the pretest"

i myself dont understand why big pharma needs the pretest to prove the potential except that humans -especially big pharma- expect everything to be handed to them on a golden platter- same reason big pharma is ready to delay the pretest study to apply for a nih grant for such when big pharma is easily able to fund the study

mits is a medical doctor and works in this kind of environment, so he is the one to answer that question